March 21, 2016 / 3:08 PM / 2 years ago

BUZZ-U.S. STOCKS ON THE MOVE-Valspar, Starwood, Valeant, IHS

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock indexes were little changed on Monday. The Dow Jones industrial average was down 0.15 percent at 17,576.1, the S&P 500 was down 0.21 percent at 2,045.25 and the Nasdaq Composite was down 0.12 percent at 4,789.91.

** VALSPAR CORP, $104.46, +24.61 pct

** SHERWIN-WILLIAMS CO, $275.61, -4.53 pct

Valspar’s shares are set to open at a record high after rival Sherwin-Williams said on Sunday it would acquire the paint maker in an all-cash deal valued at about $9.3 bln, or $113 per share.

** STARWOOD HOTELS AND RESORTS WORLDWIDE INC, $83.88, +4.11 pct

** MARRIOTT INTERNATIONAL INC, $72.295, -1.18 pct

Marriott said it made a higher offer for Starwood that was accepted by the owner of the Sheraton and Westin hotel brands.

** VALEANT PHARMACEUTICALS INTERNATIONAL INC, $30.28, +12.23 pct

The embattled Canadian drugmaker said Chief Executive Michael Pearson would step down and that the company had appointed activist investor William Ackman to its board.

** IHS INC, $117.92, +6.51 pct

** MARKIT LTD, $32.295, +9.51 pct

U.S. business research provider IHS said it would buy Markit in an all-stock deal valuing the London-based financial data company at about $5.9 billion.

** INTEL CORP, $32.08, -1.84 pct

Sanford C. Bernstein cuts the world’s largest chipmaker’s rating to “underperform” from “market perform” and price target to $26 from $29; Deutsche Bank trims to $37 from $38.

** NEW YORK MORTGAGE TRUST INC, $5.0301, +7.71 pct

The mortgage REIT declared a regular quarterly dividend of 24 cents per share in cash for the quarter ending March 31

** BIOMARIN PHARMACEUTICAL INC, $78.18, -3.41 pct

BioMarin’s drug met the main goal of reducing a toxic buildup of an amino acid in the blood of patients with a genetic disorder, but did not show benefit in related inattention and mood complications.

** AFFYMETRIX INC, $14.4, -9.94 pct

** THERMO FISHER SCIENTIFIC INC, $140, +0.00 pct

Affymetrix, a DNA-based test maker, rejected a $1.5 billion bid by Origin Technologies Corp, supporting the $1.3 bln Thermo Fisher merger deal. (Compiled by Yashaswini Swamynathan in Bengaluru; Edited by Don Sebastian)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below